Published in Antivir Ther on October 01, 2003
Total Lymphocyte Count as surrogate marker for CD4 Cell Count in HIV-Infected Individuals in Gondar University Hospital, Northwest Ethiopia. AIDS Res Ther (2012) 1.48
Relationship between total lymphocyte count (TLC) and CD4 count among peoples living with HIV, Southern Ethiopia: a retrospective evaluation. AIDS Res Ther (2008) 1.35
Determining eligibility for antiretroviral therapy in resource-limited settings using total lymphocyte counts, hemoglobin and body mass index. AIDS Res Ther (2007) 1.30
Assessment of clinico-immunological profile of newly diagnosed HIV patients presenting to a teaching hospital of eastern India. Indian J Med Res (2014) 1.02
Prediction based classification for longitudinal biomarkers. Ann Appl Stat (2010) 0.89
Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil. Int J Tuberc Lung Dis (2013) 0.83
Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children. J Acquir Immune Defic Syndr (2008) 0.79
Utility of absolute lymphocyte count as a surrogate marker of CD4 cell counts: Is it useful? Med J Armed Forces India (2013) 0.75
Absolute lymphocyte count as a surrogate marker for CD4 counts after six months of HAART initiation in a resource-limited setting in India. Indian J Med Res (2012) 0.75
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS (2003) 5.53
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS (2002) 5.21
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med (2002) 4.77
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med (2003) 4.46
Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ (2003) 4.38
Safer injection facility use and syringe sharing in injection drug users. Lancet (2005) 3.85
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ (2002) 3.70
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67
Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction (2006) 3.65
Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J (2006) 3.49
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19
Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet (2011) 3.14
Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12
The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Int J Drug Policy (2008) 3.05
Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health (2006) 3.04
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS (2007) 3.04
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (2002) 2.99
Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med (2008) 2.97
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA (2008) 2.77
Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS (2002) 2.74
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr (2005) 2.74
Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction (2010) 2.65
Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ (2004) 2.63
Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ (2004) 2.62
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis (2006) 2.61
Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis (2011) 2.55
Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend (2006) 2.53
Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ (2009) 2.51
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis (2005) 2.48
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis (2005) 2.42